Editor’s Note: The biggest IPO winners are NOT in AI, robotics or space. An overlook group of IPOs have seen crazy gains in the last couple years. This includes 756% for IonQ, 1,332% for BTQ and 2,637% for D-Wave.
Don’t worry if you missed these winners. Because a new Pre-IPO could be the next big winner. And there’s still time for you to invest.
Two of the biggest names in pharma are backing a CRISPR company going public this week.
Scribe Therapeutics (Nasdaq: SCTX)
Price Range: $13–$15
Deal Size: ~$100 million
Market Cap at IPO: ~$243 million
Expected Pricing: Thursday, July 23
Expected Trading: Friday, July 24
Scribe is a clinical-stage biotech engineering CRISPR-based gene-silencing therapies. Its lead program targets high cholesterol.
Eli Lilly (NYSE: LLY) plans to invest $10 million in the deal — around 10% of the offering. Sanofi (Nasdaq: SNY) is buying another $7.5 million through a concurrent private placement.
When large drugmakers put money into an IPO, it's a meaningful signal. We saw the same pattern with Aktis Oncology and Veradermics, where Lilly's involvement preceded strong runs.
Aktis is up 37% and Veradermics is up 544% since going public.
Scribe is worth a closer look for another reason. It's one of the first gene-editing companies to attempt an IPO in years. The last one to price was Metagenomi back in 2024. The category has been mostly frozen since biotech peaked in 2021.
The science is ambitious. Scribe uses epigenetic silencing to switch off genes without permanently cutting DNA. Its lead drug, STX-1150, targets PCSK9 — the same protein behind injectables like Repatha. The pitch is a single dose that lowers LDL cholesterol durably, instead of daily pills or quarterly shots.
The company was co-founded in 2017 by Benjamin Oakes, a former researcher in the lab of Nobel laureate Jennifer Doudna, who co-discovered CRISPR-Cas9 and serves as a scientific advisor. Backers include Andreessen Horowitz, Avoro, and OrbiMed.
This is early-stage biotech in the truest sense. STX-1150 just entered its first human trial in Australia, and initial data isn't expected until the first half of 2027. There are no approved products and no recurring revenue. A weak readout could cut the stock sharply.
Health care IPOs have returned an average of 43% in 2026, and recent biotech debuts like Kardigan and Parabilis both jumped after listing. The IPO window is for these types of biotech companies is now open.
Scribe is set to price Thursday and trade Friday.
Do you want to invest in the next big IPO – right before it starts trading?
Get all the details on my #1 new Pre-IPO for 2026.
Ian Wyatt
Editor, IPO Watch